Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma

Author:

Leypoldt Lisa B.1ORCID,Tichy Diana2ORCID,Besemer Britta3,Hänel Mathias4,Raab Marc S.5ORCID,Mann Christoph6ORCID,Munder Markus7ORCID,Reinhardt Hans Christian8,Nogai Axel9,Görner Martin10,Ko Yon-Dschun11,de Wit Maike12,Salwender Hans13ORCID,Scheid Christof14ORCID,Graeven Ullrich15ORCID,Peceny Rudolf16,Staib Peter17,Dieing Annette18,Einsele Hermann19,Jauch Anna20,Hundemer Michael21,Zago Manola22,Požek Ema2,Benner Axel2ORCID,Bokemeyer Carsten1ORCID,Goldschmidt Hartmut23ORCID,Weisel Katja C.1ORCID

Affiliation:

1. Department of Hematology, Oncology and Bone Marrow Transplantation With Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

2. Division of Biostatistics, German Cancer Research Center (DKFZ) Heidelberg, Heidelberg, Germany

3. Department of Hematology, Oncology, Immunology and Rheumatology, University Hospital of Tuebingen, Tuebingen, Germany

4. Department of Hematology, Oncology and Bone Marrow Transplantation, Klinikum Chemnitz, Chemnitz, Germany

5. Internal Medicine V and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany

6. Department of Hematology, Oncology and Immunology, University Hospital of Gießen and Marburg, Marburg, Germany

7. Department of Internal Medicine III, University Medical Center Mainz, Mainz, Germany

8. Department of Hematology and Stem Cell Transplantation, University Hospital Essen, University Duisburg-Essen, German Cancer Consortium (DKTK partner site Essen), Essen, Germany

9. Department of Internal Medicine, Charité—University Medicine Berlin, Berlin, Germany

10. Department of Hematology, Oncology and Palliative Care, Klinikum Bielefeld Mitte, Bielefeld, Germany

11. Department of Internal Medicine, Hematology and Oncology, Johanniter Krankenhaus Bonn, Bonn, Germany

12. Department of Internal Medicine, Hematology, Oncology and Palliative Medicine, Vivantes Klinikum Neukölln, Berlin, Germany

13. Asklepios Tumorzentrum Hamburg, AK Altona and AK St Georg, Hamburg, Germany

14. Department of Internal Medicine I, University Hospital Cologne, Cologne, Germany

15. Department of Hematology, Oncology and Gastroenterology, Kliniken Maria Hilf, Mönchengladbach, Germany

16. Department of Oncology, Hematology and Stem Cell Transplantation, Klinikum Osnabrück, Osnabrück, Germany

17. Department of Hematology and Oncology, St Antonius Hospital Eschweiler, Eschweiler, Germany

18. Department of Hematology and Oncology, Vivantes Klinikum am Urban, Berlin, Germany

19. Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany

20. Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany

21. Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany

22. Center for Clinical Trials, University Hospital of Tuebingen, Tuebingen, Germany

23. Internal Medicine V, GMMG-Studygroup at University Hospital Heidelberg, Heidelberg, Germany

Abstract

High, sustainable MRD negativity rates with Isa-KRd in newly diagnosed high-risk multiple myeloma (CONCEPT trial)

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Cited by 34 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3